BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3149682)

  • 1. The future streptococcal M. vaccine against rheumatic fever.
    Imran M; Jan A
    J Pak Med Assoc; 1988 Jul; 38(7):176-7. PubMed ID: 3149682
    [No Abstract]   [Full Text] [Related]  

  • 2. Changing streptococci and prospects for the global eradication of rheumatic fever.
    Stollerman GH
    Perspect Biol Med; 1997; 40(2):165-89. PubMed ID: 9058950
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine strategies to prevent rheumatic fever.
    Brandt ER; Good MF
    Immunol Res; 1999; 19(1):89-103. PubMed ID: 10374697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing epidemiology of acute rheumatic fever in the United States.
    Lee GM; Wessels MR
    Clin Infect Dis; 2006 Feb; 42(4):448-50. PubMed ID: 16421786
    [No Abstract]   [Full Text] [Related]  

  • 5. [Primary prevention of rheumatism: the status and outlook (vaccine)].
    Rotta Y
    Ter Arkh; 1985; 57(11):97-100. PubMed ID: 3909476
    [No Abstract]   [Full Text] [Related]  

  • 6. Streptococcal M protein.
    Fischetti VA
    Sci Am; 1991 Jun; 264(6):58-65. PubMed ID: 1857955
    [No Abstract]   [Full Text] [Related]  

  • 7. Group A streptococcus vaccine may be ready for phase I clinical trials in late 1989.
    Raymond CA
    JAMA; 1988 Nov; 260(19):2778. PubMed ID: 3054182
    [No Abstract]   [Full Text] [Related]  

  • 8. Decline in rheumatic fever.
    Lancet; 1985 Sep; 2(8456):647-8. PubMed ID: 2863636
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of group a streptococcal anti-M type-specific antibody in sera of rheumatic fever patients after 45 years.
    Bencivenga JF; Johnson DR; Kaplan EL
    Clin Infect Dis; 2009 Oct; 49(8):1237-9. PubMed ID: 19761409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatic fever.
    Stollerman GH
    Lancet; 1997 Mar; 349(9056):935-42. PubMed ID: 9093263
    [No Abstract]   [Full Text] [Related]  

  • 11. The changing face of rheumatic fever in the 20th century.
    Stollerman GH
    J Med Microbiol; 1998 Aug; 47(8):655-7. PubMed ID: 9877185
    [No Abstract]   [Full Text] [Related]  

  • 12. Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci.
    Pruksakorn S; Currie B; Brandt E; Martin D; Galbraith A; Phornphutkul C; Hunsakunachai S; Manmontri A; Good MF
    Lancet; 1994 Sep; 344(8923):639-42. PubMed ID: 7520963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for a group A streptococcal vaccine.
    McMillan DJ; Chhatwal GS
    Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type-specific antibodies to purified streptococcal M proteins from potentially rheumatogenic M-types in patients with rheumatic fever and rheumatic heart disease.
    Thakur A; Singhal S; Prakash K
    J Med Microbiol; 1996 Dec; 45(6):483-9. PubMed ID: 8958254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
    [No Abstract]   [Full Text] [Related]  

  • 16. Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity.
    Froude J; Gibofsky A; Buskirk DR; Khanna A; Zabriskie JB
    Curr Top Microbiol Immunol; 1989; 145():5-26. PubMed ID: 2680297
    [No Abstract]   [Full Text] [Related]  

  • 17. Pathogenesis of rheumatic fever: a review.
    Rotta J
    Ann Trop Paediatr; 1983 Mar; 3(1):1-8. PubMed ID: 6191642
    [No Abstract]   [Full Text] [Related]  

  • 18. Antigenic epitope mapping of the M24 protein of Streptococcus pyogenes: implications for serodiagnosis of rheumatic fever.
    Norton RE; Heuzenroeder M; Manning PA
    FEMS Immunol Med Microbiol; 1996 Dec; 16(3-4):267-71. PubMed ID: 9116645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Group A streptococcal antigens and vaccine potential.
    Kehoe MA
    Vaccine; 1991 Nov; 9(11):797-806. PubMed ID: 1722063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against streptococcal pharyngeal colonization with vaccines composed of M protein conserved regions.
    Fischetti VA; Bessen DE; Schneewind O; Hruby DE
    Adv Exp Med Biol; 1991; 303():159-67. PubMed ID: 1805563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.